Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-07-18
2006-07-18
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C548S253000
Reexamination Certificate
active
07078423
ABSTRACT:
The present invention relates to 5-Aryltetrazole compounds, compositions comprising a 5-Aryltetrazole compound, and methods for treating an inflammation disease, a reperfusion disease, hyperuricemia, gout, or tumor-lysis syndrome in an animal in need thereof comprising administering to the animal an effective amount of a 5-Aryltetrazole compound.
REFERENCES:
patent: 5049572 (1991-09-01), Scherrer et al.
patent: 5232937 (1993-08-01), Makovec et al.
patent: 5284954 (1994-02-01), Wittenberger
patent: 5364869 (1994-11-01), De
patent: 5663357 (1997-09-01), Teng et al.
patent: 5874593 (1999-02-01), Ushio
patent: 5976576 (1999-11-01), Makovec et al.
patent: 6191136 (2001-02-01), Marban
patent: 6191289 (2001-02-01), Ushio
patent: 6277998 (2001-08-01), Ushio
patent: 6281222 (2001-08-01), Salzman et al.
patent: 6297261 (2001-10-01), Christophersen et al.
patent: 6388088 (2002-05-01), Sidduri
patent: 6417393 (2002-07-01), Christophersen et al.
patent: 6569862 (2003-05-01), Marban
patent: 2002/0032210 (2002-03-01), Dahl et al.
patent: 2002/0037905 (2002-03-01), Dahl et al.
patent: 2002/0103202 (2002-08-01), Pinto et al.
patent: 2003/0186998 (2003-10-01), Marban
patent: 2003/0229120 (2003-12-01), Olsen et al.
patent: 0 638 553 (1994-07-01), None
patent: 10025294 (1998-01-01), None
patent: 90/09989 (1990-09-01), None
patent: 93/16053 (1993-08-01), None
patent: 98/58522 (1998-12-01), None
patent: 99/24442 (1999-05-01), None
patent: WO 99/24038 (1999-05-01), None
patent: 00/16798 (2000-03-01), None
patent: 00/24707 (2000-05-01), None
patent: 00/28979 (2000-05-01), None
patent: 00/64888 (2000-11-01), None
patent: 01/66098 (2001-09-01), None
patent: WO 01/85705 (2001-11-01), None
patent: 02/00647 (2002-01-01), None
patent: WO 02/00647 (2002-01-01), None
Oda, T., Akaike, T., Hamamoto, T., Suzuki, F., Hirano, T., and Maeda, H. 1989. Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD.Science244-974-976.
Tan, S., Yokoyama, Y., Dickens, E., Cash, T.G., Freeman, B.A., and Parks, D.A. 1993. Xanthine oxidase activity in the circulation of rats following hemorrhagic shock.Free Radic. Biot Med15:407-4 14.
McCord, J.M. 1985. Oxygen-derived free radicals in postischemic tissue injury.New Engl .J. Med.3 12:159-163.
Miesel, R., Zuber, M., Sanocka, D., Graetz, R., and Kroeger, H. 1994. Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood.Inflammation.18:597-612.
Engerson, T.D., MeKelvey, T.G., Rhyne, D.B., Boggio, E.B., Snyder, S.J., and Jones, H.P. 1987. The conversion of xanthine dehydrogenase to oxidase in ischaemic rat tissue.J. Clin. Invest.79:1564-1570.
Akaike, T., Ando, M., Tatsuya, 0., Doi, T., Ijiri, S., Araki, S., and Maeda, H. 1990. Dependence on 02 generation by xanthine oxidase of pathogenesis of influenza virus infection in mice.J. Clin. Invest.85:739-745.
Mohacsi, A.; Kozlovsky, B.; Kiss, I.; Seres, I.; Fulop, T.; Neutrophils obtained from obliterative atherosclerotic patients exhibit enchanced resting respiratory burrst and increased degranulation in response to various stimuli.Biochimica et Biophysica Acta,1316 (1996) 210-216.
Friedi, H.P., Smith, D.J., Till G.0., Thomson, P.D., Louis, D.S., and Ward, P.A. 1990. Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity.Am J Path136:491-495.
Friedl, H.P., Till, G.0., Trentz, 0., and Ward, P.A. 1989. Role of histamine, complement and xanthine oxidase in thermal injury of the skin.Am J Path135:203-2 17.
Parks, D.A., Bulkley, G.B., and Granger, D.N. 1983. Role of oxygen free radicals in shock, ischemia, and organ preservation.Surgery94:428-432.
Demling, R., LaLonde, C., Youn, Y.K., Daryani, R., Campbell, C., and Knox, J. 1992. Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes.Am Rev Respir Dis146:1272-1278.
Chambers, D.E., Parks, D.A., Patterson, G., Roy, R., McCord, J.M., Yoshida, S., Parmley, L.F., and Downey, J.M. 1985. Xanthine oxidase as a source of free radical damage in myocardial ischemia.J Mol Cell Cardiol17:145-152.
Deitch, E.A., Bridges, W., Baker, J., Ma, J.W., Ma, L., Grisham, M.B., Granger, D.N., Specian, R.D., and Berg, R. 1988. Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation.Surgery104:191-198.
Mayumi, T., Chan, C.K., Clemens, M.G., and Bulkley, G.B. 1996. Zonal heterogeneity of hepatic injury following shock/resusciation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis.Shock5:324-332.
Flynn, W.J.Jr. and Hoover, E.L. 1994. Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock.J Trauma37:956-961.
Flynn, W.J.Jr., Pilati, D., and Hoover, E.L. 1997. Xanthine oxidase inhibition prevents mesenteric blood flow deficits after resuscitated hemorrhagic shock by preserving endothelial function.J Surg Res68:175-180.
Mannion, D., Fitzpatrick, G.J., and Feeley, M. 1994. Role of xanthine oxidase inhibition in survival from hemorrhagic shock.Circ Shock42:39-43.
Cunningham, S.K. and Keaveny, T.V. 1978. Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock.Eur Surg. Res.10:305-313.
Youn, Y.K., LaLonde, C., and Demling, R. 1992. Oxidants and the pathophysiology of burn and smoke inhalation injury.Free Radic. Biol. Med.12:409-415.
Deitch, E.A., Kemper, A.C., Specian, R.D., and Berg, R.D. 1992. A study the relationship among survival, gut-origin sepsis, and bacterial translocation in a model of systemic inflammation.J Trauma32:141-147.
Anderson, B.O., Moore, E.E., Moore, F.A., Left J. A., Terada, L.S., Harken, A.H., and Repine, J.E. 1991. Hypovolemic shock promotes neutrophil sequestration in lungs by a xanthine oxidase-related mechanism.J Appl Physiol71:1862-1865.
Poggetti, R.S., Moore, F.A., Moore, E.E., Koeike, K., and Banerjee, A. 1992. Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase.J Trauma32:723-727.
Nielsen, V.G., McCammon, A.T., Tan, S., Kirk, K.A., Samuelson, P.N., and Parks, D.A. 1995. Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta occlusion and reperfusion in rabbits.J Thorac.Cardiovasc Surg.110:715-722.
Schwartz, M.D., Repine, J. E., and Abraham, E. 1995. Xanthine oxidase-derived oxygen radicals increase lung cytokine epression in mice subjected to hemorrhagic shock.Am J Respir Cell Mol Biol12:434-440.
Crowell, J.W., Jones, C.E., and Smith, E.E. 1969. Effect of allopurinol on hemorrhagic shock.Am J Phys216:744-748.
Linder, N., Rapola, J., and Raivio, K.O. 1999. Cellular expression of xanthine oxidoreductase protein in normal human tissues.Lab Invest79:967-974.
Saksela, M., Lapatto, R., and Raivio, K.O. 1998. Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues.Biol Neonate74:274-280.
Battelli, M.G., Abbondanza, A., Musiani, S., Buonamici, L., Strocchi, P., Tazzari, P.L., Gramantieri, L., and Stirpe, F. 1999. Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA).Clin Chim Acta281:147-158.
Houston, M., Estevez, A., Chumley, P., Aslan, M., Marklund, S., Parks, D.A., and Freeman, B.A. 1999. Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling.J Biol Chem274:4985-4994.
Fox, N.E. and van Kuijk, F.J. 1998. Immunohistochemical localization of xanthine oxidase in human retina.Free Radic Biol Med24:900-905.
Rouquette, M., p., 5., Bryant, R., Benboubetra, M., Stevens, C.R., Blake, D.R., Whish, W.D., Harrison, R., and Tosh, D. 1998. Xanthine oxidoreductase is asymmetirically localized on the outer surface of human endothelial and epithelial cells in culture.FEBS Lett426:397-401.
Cardillo, C., Kilcoyne, C.M., Cannon, R.O.3., Quyyumi, A.A., and Pauza, J.A. 1997. Xanthine oxidase inhibition with oxypurinol improves vasodilator function in hypercholesterlemic but
Nivorozhkin Alex
Ram Siya
Salzman Andrew
Southan Garry
Szabo Csaba
Inotek Pharmaceuticals Corporation
Wilmer Cutler Pickering Hale and Dorr LLP
LandOfFree
5-Aryltetrazole compounds, compositions thereof, and uses... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 5-Aryltetrazole compounds, compositions thereof, and uses..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5-Aryltetrazole compounds, compositions thereof, and uses... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3587989